Moody Lynn & Lieberson, LLC Bristol Myers Squibb CO Transaction History

Moody Lynn & Lieberson, LLC

$1.47 Billion
Q2 2024

A detailed history of Moody Lynn & Lieberson, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Moody Lynn & Lieberson, LLC holds 8,325 shares of BMY stock, worth $449,217. This represents 0.02% of its overall portfolio holdings.

Number of Shares

8,325

Previous 50,469 83.5%

Holding current value

$449,217

Previous $2.74 Million 87.39%

% of portfolio

0.02%

Previous 0.19%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	SELL	$40.25 - $52.99 $1.7 Million - $2.23 Million	-42,144 Reduced 83.5%	8,325 $345,000
Q1 2024 Apr 23, 2024	SELL	$47.98 - $54.4 $9.49 Million - $10.8 Million	-197,747 Reduced 79.67%	50,469 $2.74 Million
Q4 2023 Jan 24, 2024	SELL	$48.48 - $57.85 $3.05 Million - $3.64 Million	-62,882 Reduced 20.21%	248,216 $12.7 Million
Q3 2023 Oct 24, 2023	SELL	$57.89 - $64.73 $331,536 - $370,708	-5,727 Reduced 1.81%	311,098 $18.1 Million
Q2 2023 Jul 27, 2023	BUY	$63.71 - $70.74 $211,198 - $234,503	3,315 Added 1.06%	316,825 $20.3 Million
Q1 2023 May 02, 2023	SELL	$65.71 - $74.53 $422,449 - $479,153	-6,429 Reduced 2.01%	313,510 $21.7 Million
Q4 2022 Feb 01, 2023	SELL	$68.48 - $81.09 $22,324 - $26,435	-326 Reduced 0.1%	319,939 $23 Million
Q3 2022 Oct 26, 2022	SELL	$0.13 - $76.84 $5,409 - $3.2 Million	-41,614 Reduced 11.5%	320,265 $22.8 Million
Q2 2022 Jul 28, 2022	SELL	$72.62 - $79.98 $3.23 Million - $3.56 Million	-44,531 Reduced 10.96%	361,879 $27.9 Million
Q1 2022 Apr 27, 2022	BUY	$61.48 - $73.72 $1.99 Million - $2.39 Million	32,444 Added 8.68%	406,410 $29.7 Million
Q4 2021 Jan 26, 2022	BUY	$53.63 - $62.52 $2.15 Million - $2.51 Million	40,121 Added 12.02%	373,966 $23.3 Million
Q3 2021 Oct 26, 2021	SELL	$59.17 - $69.31 $277,862 - $325,479	-4,696 Reduced 1.39%	333,845 $19.8 Million
Q2 2021 Jul 28, 2021	BUY	$61.91 - $67.42 $1.7 Million - $1.86 Million	27,536 Added 8.85%	338,541 $22.6 Million
Q1 2021 Apr 23, 2021	SELL	$59.34 - $66.74 $753,677 - $847,664	-12,701 Reduced 3.92%	311,005 $19.6 Million
Q4 2020 Jan 26, 2021	BUY	$57.74 - $65.43 $203,013 - $230,051	3,516 Added 1.1%	323,706 $20.1 Million
Q3 2020 Oct 28, 2020	SELL	$57.43 - $63.64 $351,701 - $389,731	-6,124 Reduced 1.88%	320,190 $19.3 Million
Q2 2020 Jul 24, 2020	BUY	$54.82 - $64.09 $2.48 Million - $2.9 Million	45,247 Added 16.1%	326,314 $19.2 Million
Q1 2020 Apr 30, 2020	SELL	$46.4 - $67.43 $2.68 Million - $3.89 Million	-57,750 Reduced 17.04%	281,067 $15.7 Million
Q4 2019 Jan 28, 2020	BUY	$49.21 - $64.19 $7.4 Million - $9.65 Million	150,379 Added 79.8%	338,817 $21.7 Million
Q3 2019 Oct 28, 2019	SELL	$42.77 - $50.71 $2.98 Million - $3.53 Million	-69,632 Reduced 26.98%	188,438 $9.56 Million
Q2 2019 Jul 23, 2019	SELL	$44.62 - $49.34 $762,109 - $842,727	-17,080 Reduced 6.21%	258,070 $11.7 Million
Q1 2019 Apr 23, 2019	BUY	$45.12 - $53.8 $1.14 Million - $1.36 Million	25,344 Added 10.15%	275,150 $13.1 Million
Q4 2018 Jan 29, 2019	BUY	$48.76 - $63.23 $11.3 Million - $14.7 Million	232,027 Added 1305.06%	249,806 $13 Million
Q3 2018 Oct 29, 2018	BUY	$55.19 - $62.25 $1,986 - $2,241	36 Added 0.2%	17,779 $1.1 Million
Q2 2018 Jul 24, 2018	SELL	$50.53 - $62.98 $31,682 - $39,488	-627 Reduced 3.41%	17,743 $982,000
Q1 2018 Apr 27, 2018	BUY	$59.92 - $68.98 $89,041 - $102,504	1,486 Added 8.8%	18,370 $1.16 Million
Q4 2017 Feb 02, 2018	SELL	$59.94 - $65.35 $5,394 - $5,881	-90 Reduced 0.53%	16,884 $1.08 Million
Q3 2017 Nov 06, 2017	BUY	$55.23 - $63.74 $937,474 - $1.08 Million	16,974	16,974 $1.08 Million

Others Institutions Holding BMY

# of Institutions

2,407

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $115B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Moody Lynn & Lieberson, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Moody Lynn & Lieberson, LLC with notifications on news.

Account

Moody Lynn & Lieberson, LLC Bristol Myers Squibb CO Transaction History